Please reload

Recent Posts

Hiring 101 – Who, The A Method for Hiring

November 9, 2015

Please reload

Featured Posts

Spring is in the Air and — Cautiously — So are IPOs and Buyouts

April 12, 2012

Venture capital and investment funding continue to be tight for emerging companies, but the first glimmers of hope are out there — really BG Medicine, which I had the pleasure to help found, successfully launched their IPO on NASDAQ in February. Granted, they didn’t raise as much as they’d hoped in 2008; but they now have the capital to continue their biomarker/cardiovascular plans. February also saw about $75 million raised by Fluidigm, an emerging leader in microfluidics and genomics. After spending their first few years developing a protein crystallization platform, Fluidigm has wisely moved into the larger RT-PCR genomics market and are peripherally selling into the Next Gen Sequencing area. 


Next Gen Sequencing itself has been surrounded by doldrum–defying activity for a while now, and the continuation of this trend adds to the promise of a springtime economic thaw. It started in with Life Technologies spectacular acquisition of Ion Torrents. Will they hit all their milestone payments to earn the $750M?  I’d put my money on Jonathan Rothberg any day and so far it looks good. Complete Genomics, a Next Gen Sequencing service provider, contributed to the buzz by successfully raising $54M in an IPO in November.


On the diagnostics side of things, Quest Diagnostics is in buying mode and just purchased Athena Diagnostics, a small diagnostics service, for $740 million in cash. It’s a move that will help make Quest a leader in neurological disorder testing.They’ve also announced they’re buying Celera Corporation for $671 million.


It’s beginning to look like these events are part of a fresh start: an upswing in investments and in exit strategies for new companies with solid technologies and market opportunities. Here’s to spring!

Share on Twitter
Please reload

Follow Us
Please reload

Search By Tags